Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal ... Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019.

Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom improvement." The nasal spray was first approved by the ...

Spravato is made from esketamine, which is derived from ketamine—a schedule-III drug that’s FDA ... by which esketamine works as an antidepressant effect is not known, says Johnson & Johnson.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...